Immuno-oncology
Conference Coverage
Novel antibody shifts ‘eat me/don’t eat me’ balance in refractory NHL
CHICAGO – Treatment with Hu5F9-G4 (5F9) produced “encouraging” antitumor activity in a phase 1b study of 22 patients.
From the Journals
Checkpoint inhibitor shows promise in advanced squamous-cell carcinoma
The PD-1 inhibitor cemiplimab has shown a response rate in about half of patients with advanced or metastatic cutaneous squamous-cell carcinoma....
Latest News
MRD-negative status signals better outcomes in CAR T–treated ALL
CHICAGO – The study sheds light on the value of transplant after treatment with CAR T cells.
From the Journals
Metastatic lung cancer: Pembrolizumab plus chemo prolongs survival
Overall survival at 12 months in NSCLC patients treated with pembrolizumab-combination therapy was 69.2%, compared with 49.4% in patients treated...
Conference Coverage
Pembrolizumab monotherapy shows activity in advanced recurrent ovarian cancer
CHICAGO – Antitumor activity appears strongest in patients with higher PD-L1 expression in their tumors.
From the Journals
Checkpoint inhibitors well tolerated by NSCLC patients with preexisting autoimmune disease
Flares during checkpoint inhibitor therapy were generally mild, and toxicity rates were only slightly increased in NSCLC patients with AID.
Conference Coverage
Cemiplimab impresses in advanced CSCC
CHICAGO – Investigational PD-1 checkpoint inhibitor is now under FDA review for marketing approval.
Conference Coverage
Multiple solid tumors targeted by concept CAR T
PITTSBURGH – Could this CAR T therapy become a viable option against pediatric solid tumors?
From the Journals
Is cancer immunotherapy more effective in men than women?
Cancer immunotherapy with checkpoint inhibitors appears to achieve greater mortality reductions in men than in women, regardless of drug or cancer...
From the Journals
Checkpoint inhibitors get to patients quickly
Within about 4 months of FDA approval of PD-1 inhibitors, the majority of patients with melanoma, NSCLC, and RCC began receiving these agents.
Conference Coverage
New drugs provide new options in HCC
PHILADELPHIA – “We are on the cusp where new compounds not only are being tested, but they are being approved.”